Buy or sell Pear Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Pear Therapeutics Stock

Prescription digital therapeutics

Founded

2013

Notable Investors

Novartis

Headquarters

Boston MA, US

Total Funding

$134M

About Pear Therapeutics Stock

Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics (PDTs). The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better efficacy for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead products, reSET® and reSET-O®, are FDA-cleared PDTs for treating Substance Use Disorder (SUD) and Opiate Use DIsorder, respectively. Pear’s product development pipeline includes Somryst® for insomnia with depressive symptoms, as well as products for schizophrenia (Pear-004) and multiple sclerosis (Pear-006). Pear is developing and a portfolio of early-stage products across therapeutic areas.

Investors

Funding History

February 2016$20.0M
January 2018$50.0M
January 2019$64.0M

Management

Chief Executive Officer

Corey McCann

Chief Financial & Operating Officer

Chris Guiffre

Chief Medical Officer

Yuri Marcich

Chief Commercial Officer

Julia Strandberg

Chief Strategy Officer

Alex Waldron

Chief People Officer

Kathy Jeffrey

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Pear Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo